New Delhi: Reviewing the Phase III clinical trial protocol of the GZ402671 (Venglustat) presented by the pharma major Sanofi, ...

Here’s how it works. When it comes to the best cheap tablets, it's surprising how many slabs offer the perfect balance between performance and value for money. It just goes to prove that not all ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

Tablets may not be the hot new thing in 2024, but they're still excellent machines for streaming movies, playing games, or getting work done on the go. And while it seems like the best iPads ...

The internet was flooded with iPad mini 7 reviews this week after Apple's quiet announcement of the mini tablet on October 15. Given it's been three years since we last saw Apple launch an 8.3 ...

Gaming tablets offer more than just a screen for play. These devices need to juggle productivity features and entertainment options to make their prices worthwhile, all while still offering a high ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...